CordenPharma has expanded operations with new commercial oligonucleotide API manufacturing capabilities at its FDA inspected CordenPharma Colorado facility. The expansion, which was completed in the first quarter of 2018, will provide cGMP oligonucleotide manufacturing capacity up to 2mol, with a significant increase in total commercial capacity up to 500kg annually, making CordenPharma Colorado one the largest oligonucleotide manufacturing sites worldwide. The facility has not only enhanced ...